Eytan Stein

10PUBLICATIONS
130CO-AUTHORS
Regenerative medicine (incl. stem cells)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Sep 03, 2025
Combination Strategies with Menin Inhibitors for Acute Leukemia.

Ghayas C Issa, Sheng F Cai, Alex Bataller

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

|May 09, 2025
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.

Curtis A Lachowiez, Anna Barcellos, Christina M Zettler

|Apr 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.

Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari

Pageof 2

Frequent Collaborators

3 joint publications

Curtis Lachowiez

3 joint publications

Elie Traer

2 joint publications

Ghayas C Issa

2 joint publications

Courtney D DiNardo